Extraskeletal osteosarcoma in Japan: multiinstitutional study of 20 patients from the Japanese Musculoskeletal Oncology Group

Torigoe, Tomoaki; Yazawa, Yasuo; Takagi, Tatsuya; Terakado, Atsuhiko; Kurosawa, Hisashi

doi:10.1007/s00776-007-1164-8

Cited by 60 publications

(60 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In their cohort of 27 patients, 19% had an objective response to treatment; 48% had progressive disease and 33% stable disease during treatment [1]. However, some authors suggest a possible effect of chemotherapy on clinical outcomes [11,24]. In the study by GoldsteinJackson et al [11], 17 patients were treated with conventional osteosarcoma chemotherapy, which included doxorubicin, ifosfamide, cisplatin, and methotrexate.…”

Section: Discussionmentioning

confidence: 99%

“…The 3-year overall survival rate was 77%, but five patients had tumors smaller than 5 cm [11]. In the study by Torigoe et al [24], 15 patients received different forms of chemotherapy that included various combinations of doxorubicin, ifosfamide, etoposide, cisplatin, methotrexate, and carboplatin. A response rate of 45% and a 5-year overall survival rate of 66% for patients with Stage III disease was reported [24].…”

Section: Discussionmentioning

confidence: 99%

“…In the study by Torigoe et al [24], 15 patients received different forms of chemotherapy that included various combinations of doxorubicin, ifosfamide, etoposide, cisplatin, methotrexate, and carboplatin. A response rate of 45% and a 5-year overall survival rate of 66% for patients with Stage III disease was reported [24]. In one European trial, adjuvant chemotherapy in the form of cyclophosphamide, vincristine, doxorubicin, and dacarbazine (CYVADIC) reduced local recurrence but not overall survival, similar to our study [4].…”

Section: Discussionmentioning

confidence: 99%

“…There are some studies pertaining to the treatment of extraosseous osteosarcoma [1,11,14,15,20,23,24]. The prognosis seems to vary among studies, and the optimal treatment strategy has yet to be defined.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?

Fan

Patel

Lewis

et al. 2015

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Extraosseous osteosarcoma is rare, and the most appropriate therapy is unclear because there are few studies regarding its treatment. The effectiveness of radiation and chemotherapy remains uncertain owing to conflicting results in previous reports. Questions/purposes To review our experience with contemporary multimodality treatment, we asked: (1) What is the disease-specific survival and local relapse-free survival? (2) Does American Joint Commission on Cancer (AJCC) stage, tumor size, or location relate to disease outcome? (3) Does radiation therapy improve local control or survival? (4) Do doxorubicin and ifosfamide improve local control or survival? Methods Between 1990 and 2012, we treated 40 patients for localized, high-grade extraosseous osteosarcoma. In this retrospective study, we could determine the status of 36 patients (90%) either to death or for a minimum of 24 months of followup; four (10%) were lost to followup before 24 months. There were 11 patients with AJCC Stage IIA and 25 with Stage III disease. All patients underwent wide surgical excision. Of the patients with Stage IIA disease, four received radiation and none received chemotherapy. Of the patients with Stage III disease, six received radiation, seven were treated with chemotherapy, and six received radiation and chemotherapy. During the study period, high-dose doxorubicin and ifosfamide was the preferred chemotherapy regimen for patients younger than 60 years with normal cardiac and renal function. Local relapse-free survival and disease-specific survival were determined by Kaplan-Meier analysis using a prospectively maintained institutional database supplemented by information from the institutional tumor registry. The Cox proportional hazard model was used to determine the effect of various factors on local recurrence and patient survival.One of the authors certifies that he (SP), or a member of his or her immediate family, has or may receive payments or benefits, during the study period, an amount of less than USD 10,000 from CytRx (Los Angeles, CA, USA), an amount of less than 10,000 USD from Janssen Pharmaceuticals/Johnson & Johnson (Titusville, NJ, USA), and an amount of USD 10,000-USD 100,000 from Novartis (Basel, Switzerland). All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research 1 editors and board members are on file with the publication and can be viewed on request. Clinical Orthopaedics and Related Research 1 neither advocates nor endorses the use of any treatment, drug, or device. Readers are encouraged to always seek additional information, including FDA-approval status, of any drug or device prior to clinical use. Each author certifies that his or her institution approved the human protocol for this investigation, that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained. Results At 5 years, local relapse-free survival was 47% (95% CI, 27%-64%), and disease-spe...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?

Fan

Patel

Lewis

et al. 2015

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

show abstract

“…Typically EOSs arise as large, deep and painless lesions in the lower extremities, most commonly in the thigh. Unlike skeletal osteosarcoma, which predominantly affects patients in the second and third decades of life, EOSs are frequently observed in patients aged >50 years at the time of diagnosis (1)(2)(3)(4)(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report

et al. 2015

View full text Add to dashboard Cite

Abstract. Extraskeletal osteosarcomas (EOSs) are rare variants of primary osteosarcoma of the bone, and are defined as sarcomas located in the soft tissues and characterized by osteoid production. EOS exhibits distinctive demographic, imaging and prognostic features compared with osteosarcoma of bone origin. The available data are contradictory with regard to the use of chemotherapy regimens in the management of EOS. The present study describes a case of EOS that progressed following two lines of therapy oriented to soft-tissue and bone sarcoma histology, respectively. As a gemcitabine-docetaxel combination schedule has demonstrated synergistic activity against bone and soft-tissue sarcoma histologies, this chemotherapy regimen was selected as salvage therapy. The treatment was well-tolerated and induced a long lasting partial response for ~14 months. To the best of our knowledge, this is the first report involving the clinical use of this combination regimen for the treatment of EOS. Furthermore, as demonstrated in this report, EOS may maintain relative chemosensitivity, indicating the potential to control advanced disease in the long term and to plan subsequent chemotherapy regimens.

show abstract

Particular Aspects

2011

Soft Tissue Tumors

View full text Add to dashboard Cite

Extraskeletal osteosarcoma in Japan: multiinstitutional study of 20 patients from the Japanese Musculoskeletal Oncology Group

Cited by 60 publications

References 19 publications

Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?

Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?

Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report

Particular Aspects

Contact Info

Product

Resources

About